Globus Medical price target raised to $100 from $92 at RBC Capital

RBC Capital analyst Shagun Singh raised the firm’s price target on Globus Medical (GMED) to $100 from $92 and keeps an Outperform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC believes it is poised to deliver a solid year of underlying sales growth, estimating 4%-5% y/y growth as the initial target in a low-single-digit growth market that is likely to prove conservative.